Jaguar Health Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Jaguar Health wird ein Gewinn- und Umsatzwachstum von 25.9% bzw. 34.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 66.4% pro Jahr wachsen soll.

Wichtige Informationen

25.9%

Wachstumsrate der Gewinne

66.4%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.9%
Wachstumsrate der Einnahmen	34.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	19 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09

Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jul 24

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

May 24

Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Mar 29

Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Jan 22

Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jun 10

Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jan 23

Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment

Oct 17

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Aug 25

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Aug 19

Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients

Jan 11

Jaguar Health leaps higher in new year

Jan 05

Jaguar Health inks second Mytesi royalties agreement for $6M

Dec 23

Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Dec 02

Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%

Nov 30

Jaguar Health EPS misses by $0.10, misses on revenue

Nov 16

Jaguar Health receives positive Nasdaq listing determination

Oct 29

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:JAGX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	22	-20	N/A	-25	1
12/31/2025	16	-27	N/A	-24	1
12/31/2024	11	-36	N/A	-26	1
9/30/2024	10	-38	-29	-29	N/A
6/30/2024	10	-36	-29	-29	N/A
3/31/2024	10	-38	-30	-30	N/A
12/31/2023	10	-41	-33	-33	N/A
9/30/2023	11	-40	-33	-32	N/A
6/30/2023	11	-44	-34	-34	N/A
3/31/2023	11	-42	-37	-35	N/A
12/31/2022	12	-47	-35	-33	N/A
9/30/2022	11	-54	-37	-36	N/A
6/30/2022	8	-54	-38	-37	N/A
3/31/2022	6	-59	-36	-36	N/A
12/31/2021	4	-53	-35	-35	N/A
9/30/2021	5	-50	-30	-30	N/A
6/30/2021	7	-46	-24	-24	N/A
3/31/2021	10	-42	-18	-18	N/A
12/31/2020	9	-39	-15	-15	N/A
9/30/2020	8	-35	-14	-14	N/A
6/30/2020	7	-39	-20	-20	N/A
3/31/2020	5	-45	-21	-21	N/A
12/31/2019	6	-45	-20	-20	N/A
9/30/2019	6	-48	-22	-22	N/A
6/30/2019	6	-43	-16	-16	N/A
3/31/2019	5	-34	-17	-17	N/A
12/31/2018	4	-32	-23	-23	N/A
9/30/2018	4	-41	-23	-23	N/A
6/30/2018	4	-30	N/A	-23	N/A
3/31/2018	4	-24	N/A	-19	N/A
12/31/2017	4	-22	N/A	-10	N/A
9/30/2017	3	-5	N/A	-7	N/A
6/30/2017	2	-14	N/A	-17	N/A
3/31/2017	1	-17	N/A	-15	N/A
12/31/2016	0	-15	N/A	-14	N/A
12/31/2015	0	5	N/A	1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: JAGX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: JAGX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: JAGX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: JAGXDie Einnahmen des Unternehmens (34.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: JAGXDie Einnahmen des Unternehmens (34.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von JAGX in 3 Jahren voraussichtlich hoch sein wird

Jaguar Health Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 11%

Consensus EPS estimates fall by 13%

Price target decreased to US$4.00

Recent updates

Consensus revenue estimates fall by 11%

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

FDA Approves Renewal of Canalevia-CA1, Jaguar Health, Inc.'s Drug for Chemotherapy-Induced Diarrhea in Dogs

New major risk - Market cap size

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024

New major risk - Market cap size

Consensus EPS estimates fall by 13%

Jaguar Health, Inc. Announces Issuance of New Hong Kong Patent Bolsters Ip Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Jaguar Health, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Napo Pharmaceuticals Announces Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders

New major risk - Market cap size

Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jaguar Health, Inc. Reports Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. to Report Q1, 2024 Results on May 14, 2024

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Full year 2023 earnings released: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Jaguar Health, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health, Inc. announced that it has received $0.06 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New major risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome

Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease

New major risk - Market cap size

Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

First quarter 2023 earnings released: US$2.39 loss per share (vs US$30.17 loss in 1Q 2022)

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health, Inc. to Report Q1, 2023 Results on May 15, 2023

Jaguar Health, Inc. announced that it has received $1.86 million in funding

Jaguar Health, Inc. announced that it expects to receive $1.86 million in funding

Full year 2022 earnings: Revenues in line with analyst expectations

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. Provides Updates Regarding its Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Price target decreased to US$4.00

Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (Cid) in Breast Cancer Patients

European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease

Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Jaguar Health, Inc. announced delayed 10-Q filing

Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Jaguar stock rises on license deal with SynWorld for Canalevia in China

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory

Jaguar Health Regains Compliance with Nasdaq Bid Price Requirement

Jaguar Health shares jumps 13% after pricing $15M direct offering